SynthesisEuropean journal of clinical pharmacology2020
Systematic review and meta-analysis of the efficacy of clinically tested protectants of cisplatin nephrotoxicity.
Synthesis in European journal of clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Glutathione in Skin Aging and Tissue Regeneration: A Systematic Review of Molecular Mechanisms, Redox Modulation, and Biomedical Implications.Molecules (Basel, Switzerland) · 2026Pooled it
- Mannitol for prevention of cisplatin-induced nephrotoxicity: a systematic review and meta-analysis of randomized controlled trials.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Pooled it
- Hydration Methods for Cisplatin Containing Chemotherapy: A Systematic Review.The oncologist · 2024Pooled it
- Disparities in Cisplatin-Induced Cytotoxicity-A Meta-Analysis of Selected Cancer Cell Lines.Molecules (Basel, Switzerland) · 2023Pooled it
- Maternal-Fetal Exposure to Oncoelements and Their Oxidative and Epigenetic Impact on Pregnancy Outcomes.International journal of molecular sciences · 2026Review
- Protective effect of abietic acid nanoparticles synthesized by gamma-irradiation against cisplatin-induced renal injury in mice: a promising novel natural nano-drug.Molecular biology reports · 2025Article
- Review
- Review
- Crizotinib Inhibits Viability, Migration, and Invasion by Suppressing theCurrent oncology (Toronto, Ont.) · 2025Article
- The effect of different combinations of flaxseed, melatonin, gum acacia, and betaine on diabetic rats with adenine-induced chronic kidney disease.Frontiers in pharmacology · 2025Article
- The renoprotective potential of montelukast: a scoping review.Annals of medicine and surgery (2012) · 2024Article
- Article
- GSTT1/GSTM1 deficiency aggravated cisplatin-induced acute kidney injury via ROS-triggered ferroptosis.Frontiers in immunology · 2024Article
- Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches.Frontiers in nephrology · 2024Review
- Application of arterial infusion ports in hepatic arterial infusion chemotherapy and embolization for advanced hepatocellular carcinoma.Saudi medical journal · 2023Article
- Cisplatin in Liver Cancer Therapy.International journal of molecular sciences · 2023Review
- Electrolytes Play a Role in Detecting Cisplatin-Induced Kidney Complications and May Even Prevent Them-Retrospective Analysis.Medicina (Kaunas, Lithuania) · 2023Article
- Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies.Investigative and clinical urology · 2023Review
- Protective effect of spore oil-functionalized nano-selenium system on cisplatin-induced nephrotoxicity by regulating oxidative stress-mediated pathways and activating immune response.Journal of nanobiotechnology · 2023Article
- Efficacy of Short Hydration for Intermediate to High-Dose Cisplatin-Based Chemotherapy for Outpatients: SHORTCIS Trial.Asian Pacific journal of cancer prevention : APJCP · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionCisplatin is a potent antineoplastic drug that has been widely used to treat a number of solid tumors. However, a high incidence of renal damage observed in patients has led researchers to search for alternate strategies that prevent or at least reduce the cisplatin-induced nephrotoxicity. The objective of the present study was to conduct a systematic review and a subsequent meta-analysis to evaluate and identify compounds with effective antitumor activity and lesser side effects that could provide protection against cisplatin-induced nephrotoxicity.
methodsThe study included all placebo-controlled trials published up to December 2017 that met the inclusion criteria. A total of 22 articles were finally included to extract the following information: number of patients, doses of cisplatin and protectant, qualitative (acute kidney injury incidence) and quantitative (plasma creatinine, blood urea nitrogen, and creatinine clearance) indicators of renal function. The odds ratio or the mean difference (95% confidence interval) of each parameter was calculated for each study and group of studies.
resultsThe results of this meta-analysis show that there is great variability in the nephroprotective capacity of a variety of products evaluated. Of all the compounds tested, only magnesium sulfate and cystone were found to exert protective effects. However, more studies need to be conducted to confirm these results.
conclusionsThe administration of 1 g of Mg i.v. seems to be the best strategy for the prevention of cisplatin nephrotoxicity.
Indexed as
Identifiers
31677116What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.